Tags

Type your tag names separated by a space and hit enter

Reversal of "atypical"-multidrug resistance by recombinant human tumor necrosis factor in the human ovarian cancer cell line A2780-DX3.
Oncol Res. 1993; 5(8):311-23.OR

Abstract

A2780 human ovarian cancer cell line and its multidrug resistant counterpart A2780-DX3 were utilized for this in vitro study. A2780-DX3 is resistant in various degrees to several topoisomerase II inhibitors but sensitive to vinca alkaloids. Simultaneous treatment of the A2780-DX3 line with 1000 U/mL rHuTNF largely reverses resistance to most topoisomerase II inhibitors. By itself, 1000 U/mL rHuTNF is not toxic to the resistant line. Uptake and retention of [3H]-Mitoxantrone are not modified by rHuTNF, whereas rHuTNF is very active in potentiating the effects of Mitoxantrone. After treatment with topoisomerase II inhibitors, Doxorubicin, Mitoxantrone, or VP16, rHuTNF restores DNA-SSB and DNA-protein cross-links in the resistant line to the level of the wild type. The cleavage activity of topoisomerase II in the resistant line is about 40% of the level present in the parental line. Five minutes after the addition of 1000 U/mL of rHuTNF, the cleavage activity in the resistant line is about 85% of the level present in the parental line. The catalytic activity of topoisomerase II is only 15% lower in the resistant line, but it is increased by about 50% 5 min after the addition of rHuTNF to the resistant line. These effects are transient and cannot be observed after 30 min. These transient direct effects of rHuTNF on topoisomerase II could be associated with its ability to restore sensitivity to inhibitors of topoisomerase II in the A2780-DX3 line.

Authors+Show Affiliations

Department of Chemical Carcinogenesis, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

8012063

Citation

Cimoli, G, et al. "Reversal of "atypical"-multidrug Resistance By Recombinant Human Tumor Necrosis Factor in the Human Ovarian Cancer Cell Line A2780-DX3." Oncology Research, vol. 5, no. 8, 1993, pp. 311-23.
Cimoli G, Valenti M, Parodi S, et al. Reversal of "atypical"-multidrug resistance by recombinant human tumor necrosis factor in the human ovarian cancer cell line A2780-DX3. Oncol Res. 1993;5(8):311-23.
Cimoli, G., Valenti, M., Parodi, S., Mazzoni, A., De Sessa, F., Conte, P., & Russo, P. (1993). Reversal of "atypical"-multidrug resistance by recombinant human tumor necrosis factor in the human ovarian cancer cell line A2780-DX3. Oncology Research, 5(8), 311-23.
Cimoli G, et al. Reversal of "atypical"-multidrug Resistance By Recombinant Human Tumor Necrosis Factor in the Human Ovarian Cancer Cell Line A2780-DX3. Oncol Res. 1993;5(8):311-23. PubMed PMID: 8012063.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Reversal of "atypical"-multidrug resistance by recombinant human tumor necrosis factor in the human ovarian cancer cell line A2780-DX3. AU - Cimoli,G, AU - Valenti,M, AU - Parodi,S, AU - Mazzoni,A, AU - De Sessa,F, AU - Conte,P, AU - Russo,P, PY - 1993/1/1/pubmed PY - 1993/1/1/medline PY - 1993/1/1/entrez SP - 311 EP - 23 JF - Oncology research JO - Oncol Res VL - 5 IS - 8 N2 - A2780 human ovarian cancer cell line and its multidrug resistant counterpart A2780-DX3 were utilized for this in vitro study. A2780-DX3 is resistant in various degrees to several topoisomerase II inhibitors but sensitive to vinca alkaloids. Simultaneous treatment of the A2780-DX3 line with 1000 U/mL rHuTNF largely reverses resistance to most topoisomerase II inhibitors. By itself, 1000 U/mL rHuTNF is not toxic to the resistant line. Uptake and retention of [3H]-Mitoxantrone are not modified by rHuTNF, whereas rHuTNF is very active in potentiating the effects of Mitoxantrone. After treatment with topoisomerase II inhibitors, Doxorubicin, Mitoxantrone, or VP16, rHuTNF restores DNA-SSB and DNA-protein cross-links in the resistant line to the level of the wild type. The cleavage activity of topoisomerase II in the resistant line is about 40% of the level present in the parental line. Five minutes after the addition of 1000 U/mL of rHuTNF, the cleavage activity in the resistant line is about 85% of the level present in the parental line. The catalytic activity of topoisomerase II is only 15% lower in the resistant line, but it is increased by about 50% 5 min after the addition of rHuTNF to the resistant line. These effects are transient and cannot be observed after 30 min. These transient direct effects of rHuTNF on topoisomerase II could be associated with its ability to restore sensitivity to inhibitors of topoisomerase II in the A2780-DX3 line. SN - 0965-0407 UR - https://www.unboundmedicine.com/medline/citation/8012063/Reversal_of_"atypical"_multidrug_resistance_by_recombinant_human_tumor_necrosis_factor_in_the_human_ovarian_cancer_cell_line_A2780_DX3_ L2 - https://web.expasy.org/cellosaurus/CVCL_0134 DB - PRIME DP - Unbound Medicine ER -